Institutional members access full text with Ovid®

Share this article on:

The right diagnostic work-up: investigating renal and renovascular disorders

Radermacher, Jörg; Haller, Hermann

Hypertension: From Treatment Resistance to Optimal Therapy: A Satellite Symposium to the 19th ISH/12th ESH Meeting; June 23, 2002, Prague: Review

Renovascular disease is present in about 10-40% of patients with end-stage renal disease, and constitutes the fastest-growing group of end-stage renal disease patients. The unselective correction of renal artery stenosis has led to disappointing results. Most studies that have compared conservative treatment with angioplasty have found only modest or no beneficial effects of angioplasty on renal function and blood pressure. It is therefore mandatory to evaluate the functional significance of a stenosis before intervention. Patients most likely to respond favourably to revascularization should be identified. Factors that affect outcome include the severity of renal artery stenosis, type of treatment of renal artery stenosis and, most importantly, underlying renal disease, which prevents a favourable response even after successful correction of renal artery stenosis. Doppler ultrasonography to evaluate the renal resistance index [1 − (end diastolic velocity/maximum systolic velocity) × 100] or captopril scintigraphy are the best methods by which to classify patients as responders or non-responders to intervention. In patients with a renal resistance index ≥80%, improvement of renal function or blood pressure is highly unlikely, despite successful correction of renal artery stenosis. The value of the renal resistance index can also be extended to patients with non-stenotic renal diseases. Identifying patients at risk for irreversible loss of renal function and who may benefit from intervention is a high research priority.

Department of Nephrology, Hannover Medical School, Hannover, Germany.

Correspondence and requests for reprints to Dr Jörg Radermacher, Department of Nephrology, Medizinische Hochschule Hannover, PO Box 61 01 80, D-30625 Hannover, Germany. Tel: +49 511 5326305; fax: +49 511 552366; e-mail:

© 2003 Wolters Kluwer Health | Lippincott Williams & Wilkins